Here we designed this open-label, randomized feasibility trial to evaluate the feasibility, efficacy and tolerability of neoadjuvant everolimus combined with letrozole versus neoadjuvant FEC chemotherapy in postmenopausal women with ER-positive, HER2-negative breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.